A double-blinded randomized clinical trial involving 10 female and 31 male adults (mean age 43.6 years) with MASLD assessing the impact of daily 250 mg genistein supplementation for 8 weeks reported reduced serum levels of insulin ( P = .001), homeostasis model assessment for insulin resistance ( P = .041), serum IL-6 ( P = .018), serum TNF- ( P = .045), serum malondialdehyde ( P = .004), and waist to hip ratio ( P = .021) with genistein compared to placebo (162)
He worries that people will think that these peptides have robust clinical evidence behind them as a result of being added to the list
It is not intended for: Human consumption Veterinary use Diagnostic, therapeutic, or preventative applications No instructions, protocols, dosing information, or usage guidance are provided or implied
It is a metabolic engine that drives inflammation, insulin resistance, and cardiovascular risk